| General Information | |
|---|---|
| ZINC ID | ZINC000042878600 |
| Molecular Weight (Da) | 534 |
| SMILES | CCCCOCc1c(-c2nnc(C(C)(C)C)o2)nn(-c2ccc(Cl)cc2Cl)c1-c1ccc(Cl)cc1 |
| Molecular Formula | C26Cl3N4O2 |
| Action | Antagonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 142.825 |
| HBA | 5 |
| HBD | 0 |
| Rotatable Bonds | 9 |
| Heavy Atoms | 35 |
| LogP | 8.193 |
| Activity (Ki) in nM | 112.202 |
| Polar Surface Area (PSA) | 65.97 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | + |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | - |
| Acute oral toxicity | + |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 0.96000027 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 22 |
| Fraction csp3 | 0.35 |
| Ilogp | 5 |
| Xlogp3 | 7.57 |
| Wlogp | 8.01 |
| Mlogp | 5.36 |
| Silicos-it log p | 7.69 |
| Consensus log p | 6.73 |
| Esol log s | -7.79 |
| Esol solubility (mg/ml) | 0.00000865 |
| Esol solubility (mol/l) | 1.62E-08 |
| Esol class | Poorly sol |
| Ali log s | -8.79 |
| Ali solubility (mg/ml) | 0.00000086 |
| Ali solubility (mol/l) | 1.61E-09 |
| Ali class | Poorly sol |
| Silicos-it logsw | -11.02 |
| Silicos-it solubility (mg/ml) | 5.13E-09 |
| Silicos-it solubility (mol/l) | 9.62E-12 |
| Silicos-it class | Insoluble |
| Pgp substrate | |
| Log kp (cm/s) | -4.18 |
| Lipinski number of violations | 2 |
| Ghose number of violations | 3 |
| Veber number of violations | 0 |
| Egan number of violations | 1 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.17 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 3 |
| Synthetic accessibility | 4.19 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -7.023 |
| Logd | 5.213 |
| Logp | 6.9 |
| F (20%) | 0.001 |
| F (30%) | 0.004 |
| Mdck | - |
| Ppb | 99.40% |
| Vdss | 4.388 |
| Fu | 2.07% |
| Cyp1a2-inh | 0.165 |
| Cyp1a2-sub | 0.611 |
| Cyp2c19-inh | 0.801 |
| Cyp2c19-sub | 0.088 |
| Cl | 4.121 |
| T12 | 0.02 |
| H-ht | 0.219 |
| Dili | 0.982 |
| Roa | 0.635 |
| Fdamdd | 0.101 |
| Skinsen | 0.042 |
| Ec | 0.003 |
| Ei | 0.009 |
| Respiratory | 0.543 |
| Bcf | 3.06 |
| Igc50 | 5.235 |
| Lc50 | 6.736 |
| Lc50dm | 5.379 |
| Nr-ar | 0.001 |
| Nr-ar-lbd | 0.075 |
| Nr-ahr | 0.073 |
| Nr-aromatase | 0.972 |
| Nr-er | 0.856 |
| Nr-er-lbd | 0.554 |
| Nr-ppar-gamma | 0.618 |
| Sr-are | 0.931 |
| Sr-atad5 | 0.011 |
| Sr-hse | 0.279 |
| Sr-mmp | 0.959 |
| Sr-p53 | 0.868 |
| Vol | 504.862 |
| Dense | 1.054 |
| Flex | 0.409 |
| Nstereo | 0 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 4 |
| Skin sensitization | 0 |
| Acute aquatic toxicity | - |
| Toxicophores | 1 |
| Qed | 0.214 |
| Synth | 2.784 |
| Fsp3 | 0.346 |
| Mce-18 | 26 |
| Natural product-likeness | -1.212 |
| Alarm nmr | 0 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Rejected |